iNCOVACC: BBV154 - novel adenovirus vectored, intranasal vaccine for COVID-19, developed by Bharat Biotech in collaboration with Biotechnology Industry Research Assistance was launched on Republic day by the Union Health minister.

Approved for Primary,  2-dose series:  8 drops (0.5 mL per dose), 4 drops are administered into each nostril.
Single booster dose: at ≥6 months after completion of primary schedule of Covishield or Covaxin.

Characteristics of iNCOVACC

Stimulate both local and systemic immune response.

Likely to prevent infection and transmission of COVID-19.

Non-invasive, Needle-free (eliminating associated risks of injuries and infection).

 Ease of administration – does not require trained health care workers.

Rollout to begin in private hospitals; at Rs 325 a dose.